Emcure Pharmaceuticals Pvt. Ltd., one of the paramount pharmaceutical manufacturing companies in India was incorporated as on April 16, 1981. We have maintained our stride of pharmaceutical innovation and development since past 36 years and as history is the witness, we will continue doing so!
Our Company was incorporated as Emcure Pharmaceuticals Private Limited on April 16, 1981 as a private limited company under the Companies Act, 1956. Our name embodies our purpose and core belief of the entire company which is to make Effective Medicine to Cure patients for enabling them to lead healthier lives.
We are a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Our core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which we commercialize through our marketing infrastructure across geographies and relationships with multi-national pharmaceutical companies.
We are ranked as the 12th largest pharmaceutical company (Source: AIOCD Jan MAT 2017) in India in terms of market share based on the domestic sales of pharmaceutical products. We believe that our competitive advantage in the domestic market lies in our established presence in all major therapeutic areas including blood related, cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, vitamins, minerals and nutrients products. We have also recently entered the oncology ,diabetes & neuroscience therapeutic areas.
We have a well-diversified income base thanks to our business in the international markets. We have our own sales and marketing infrastructure in the United States through our subsidiary, Heritage. We sell our portfolio of branded generic products to rest of the world. Our products are currently shipped to over 70 countries, where we have established our presence by focusing on important alliances with local and multi-national companies which stand at leadership positions in the therapeutic areas on which we focus. We have subsidiaries in Dubai, Brazil, South Africa, Singapore & Nigeria and branch offices in Russia & Morocco.
We focus our research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules and biosimilars, and novel drug delivery systems. We have a portfolio of 11 chiral molecules, eight of which we launched for the first time in India. We also have capabilities to develop complex products, including difficult iron preparations, oncology drugs and controlled release products.
After starting its journey in 1981, Emcure Pharmaceuticals Pvt. Ltd. was converted to a public company ten years later and named Emcure Pharmaceutical Limited. In last 3 decades, Emcure Pharmaceutical Pvt. Ltd. has grown in terms of tangible and intangible assets. Starting from employing more number of employees, researchers, scientists to collaborating with dominant players in international pharmaceutical market, Emcure’s growth has been consistently progressive. Over the period, we have accumulated and forged commercial alliances and market influence by implementing several corporate compliance functions and strategic acquisition plans.
We have established ourselves within the ranks of credible pharma research companies in india through constant innovation and expansion. After the incorporation, Emcure launched its first manufacturing facility in Bhosri, Pune in 1983. It wasn’t a long wait for us to launch our first Chiral product named Asomex (S- Amlodipine). After that, the string of subsidiaries which were later incorporated in the company started. In 2002, Emcure incorporated Zuventus Healthcare Limited followed by Emcure Pharmaceuticals USA Inc. in 2004. Emcure implemented the clever combination of vertical and horizontal growth aspects, owing to which we managed to continue expanding.
2005 was a momentous year for us as we established 1 st USFDA approval Solid Oral facility at Hinjawadi, Pune. The streak continued in 2006 as well when Emcure established its API facility at Kurkumbh. That was also the year when the injectables Facility and Emcure Biotech Ltd. Facility operations commenced and Blackstone, the asset management company invested in the company. 2009 and 2010 were also stupendous for the company as we extended our reach in Jammy and then, Dubai. Solid Oral Facility at Jammu and Emcure Pharmaceutical Mena FZ-LLC in Dubai added extra glimmer to our enterprise. Moreover, in the year 2010, Emcure stepped into the Neuroscience Division and established a facility on 2 nd February 2010.
We were aware of the fact that just the domestic expansion won't help our cause of spreading healthcare and wellness in the world. So we commenced our sales and marketing operations in the United States through our acquisition of Heritage in April 2011. In the following years, we established our strong foothold in other regions such as Africa, the Commonwealth of Independent States, Latin America, the Middle East, and South East Asia along with it 70 other countries. In addition to spreading our consumer network in these regions, we also formed business relations with companies like Pfizer, BMS, Teva, Sandoz, Mylan, Sagent, etc. While maintaining the same growth pattern, Emcure earned respect and brand image in the market. As a result of that, We were ranked as the 12'th largest pharmaceutical company. Our growing trajectory is consistent as in August 2016, Emcure has forayed into the fast growing arena of Dermatology.
Emcure is an exponentially expanding company and our diligent dedication will ensure that the future of the company will stay bright while the history remains as a testament to it.
Sanand Injectables facility commenced
USFDA approval of Sanand and F-II (API)
US manufacturing facility expansion
Acquired Bharadwaj Pharma GMBH in Germany
Acquired Marcan Pharmaceuticals Inc. in Canada
Acquired Tillomed Laboratories, UK
Bain capital bought Blackstone’s stake in Emcure
Worldwide rights of BICNU acquired
Acquired Heritage Pharmaceuticals Holdings Inc.
Cytotoxic facility commenced in Hinjewadi
Solid Dosage facility at Jammu commenced
USFDA approvals for injectables facility at Hinjewadi
1st in-house biosimilar TNK-Tpa launched
Blackstone invests in the company
API facility at Kurkumbh commenced
Injectables & Emcure Biotech Ltd. (now Gennova biopharmaceuticals limited) facility operational
Solid Oral facility @ Hinjawadi commenced & 1st USFDA approval granted
Emcure Pharmaceutical USA (now Heritage pharmaceutical labs) incorporated & in-house API R&D commenced
Zuventus Healthcare Limited incorporated & 1st Chiral product launched
Gennova biopharmaceuticals limited incorporated
Launched India Formulations Business
1st manufacturing facility operational in Bhosari
Emcure Pharmaceuticals Pvt. Ltd. Incorporated
Emerge as a technology-driven global player offering high quality and cost effective healthcare
Our Core Values
Heritage Pharma Labs Inc. Announces Acquisition of 23 FDA-Approved ANDAs
East Brunswick, NJ, February 6, 2019 – Heritage Pharma Labs Inc. (Heritage) today announced that they have acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA). Financial terms were not disclosed. Of the newly acquired products, Heritage and its parent company, Emcure Pharmaceuticals Ltd. had previously manufactured most of these products under a supply agreement with a third party, and Heritage plans to launch all of these products into the U.S. market under a Heritage label with immediate availability starting in Q2 2019 through its affiliate, Heritage Pharmaceuticals Inc.Download Press Release »